Pemvidutide, Altimmune’s experimental therapy, significantly reduced liver fat and inflammation, as well as body weight, among overweight or obese people with metabolic dysfunction-associated…
Having persistently high blood levels of bilirubin, a marker of liver damage, a year after undergoing a corrective liver surgery called the Kasai procedure increases…
In its efforts to connect diagnosed but untreated hepatitis B or C patients with physicians, the Center for Disease Analysis (CDA) Foundation has…
A European Medicines Agency (EMA) committee has recommended the approval of Ipsen‘s Iqirvo (elafibranor) as a second-line therapy for adults with primary biliary…
Measuring blood levels of bile acids, a component of bile, and the gamma-glutamyl transferase (GGT) enzyme may aid newborn cholestasis diagnosis by distinguishing between…
Poor sleep quality — noted by researchers as increasingly common in modern society — is significantly linked to a higher chance of having metabolic dysfunction-associated…
The use of dupilumab, an approved anti-inflammatory antibody-based treatment, worked to ease itching, known medically as pruritus, in a young woman with Alagille syndrome…
The U.S. Food and Drug Administration (FDA) has approved a label expansion for Livmarli (maralixibat) that allows the medication to be used in patients with…
World Hepatitis Day, marked annually on July 28, seeks to raise awareness and help efforts to end viral hepatitis, a condition marked by liver…
NGM Biopharmaceuticals has raised $122 million in financing, which the California-based company will use to help launch a planned registrational clinical trial to test…